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ABSTRACT Streptococcus pneumoniae (the pneumococcus) carriage is commonly used
to measure effects of pneumococcal vaccines. Based on findings from culture-based
studies, the World Health Organization recommends both nasopharyngeal (NP) and oro-
pharyngeal (OP) sampling for detecting adult carriage. Given evidence of potential con-
founding by other streptococci, we evaluated molecular methods for pneumococcal
identification and serotyping from 250 OP samples collected from adults in Fiji, using
paired NP samples for comparison. Samples were screened using lytA quantitative PCR
(qPCR), as well as pneumococcal identification and serotyping conducted by DNA mi-
croarray. A subset of OP samples were characterized by latex sweep agglutination and
multiplex PCR. Alternate qPCR assays (piaB and bguR) for pneumococcal identification
were evaluated. The lytA qPCR was less specific and had poor positive predictive value
(PPV) in OP samples (88% and 26%, respectively) compared with NP samples (95% and
64%, respectively). Using additional targets piaB and/or bguR improved qPCR specificity
in OP, although the PPV (42 to 53%) was still poor. Using microarray, we found that
102/107 (95%) of OP samples contained nonpneumococcal streptococci with partial or
divergent complements of pneumococcal capsule genes. We explored 91 colonies iso-
lated from 11 OP samples using various techniques, including multiplex PCR, latex ag-
glutination, and microarray. We found that nonpneumococcal streptococci contribute to
false positives in pneumococcal serotyping and may also contribute to spurious identifi-
cation by qPCR. Our results highlight that molecular approaches should include multiple
loci to minimize false-positive results when testing OP samples. Regardless of method,
pneumococcal identification and serotyping results from OP samples should be inter-
preted with caution.
IMPORTANCE Streptococcus pneumoniae (the pneumococcus) is a significant global
pathogen. Accurate identification and serotyping are vital. In contrast with World Health
Organization recommendations based on culture methods, we demonstrate that pneu-
mococcal identification and serotyping with molecular methods are affected by sample
type. Results from oropharyngeal samples from adults were often inaccurate. This is par-
ticularly important for assessment of vaccine impact using carriage studies, particularly in
low- and middle-income countries where there are significant barriers for disease surveil-
lance.
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The Gram-positive bacterium Streptococcus pneumoniae (the pneumococcus) causesa range of diseases, including otitis media, pneumonia, and meningitis. Pneumo-
cocci are a significant cause of morbidity and mortality worldwide, particularly in young
children and older adults (1, 2). Colonization, and subsequent carriage, of pneumococci
in the upper airways (particularly the nasopharynx and oropharynx) is considered a
prerequisite for pneumococcal disease and transmission (3). Carriage of pneumococci
in healthy individuals is generally asymptomatic (3, 4). Pneumococcal conjugate vac-
cines (PCVs) targeting the pneumococcal polysaccharide capsule (current pediatric
formulations contain 10 and 13 serotypes) have substantially reduced pneumococcal
disease caused by vaccine-type pneumococci (5). In some settings, a subsequent
increase in disease caused by nonvaccine serotypes has partially offset the benefits of
PCVs (6, 7). PCVs also reduce carriage of vaccine-type pneumococci (8, 9). This, in turn,
reduces transmission of pneumococci to unvaccinated individuals and therefore pro-
tects unvaccinated age groups within a population through indirect (or herd) effects.
Carriage studies are used to measure direct and indirect effects of pneumococcal
vaccination in a population, particularly in low- or middle-income settings that lack
robust disease surveillance systems (10). In children, pneumococci are primarily found
in the nasopharynx, and so carriage is normally determined by testing nasopharyngeal
(NP) swab specimens (11, 12). In contrast, pneumococcal carriage in adults is more
evenly distributed between the nasopharynx and the oropharynx (13–16). Therefore,
the World Health Organization (WHO) recommends collecting both oropharyngeal (OP)
and NP samples for the detection of pneumococcal carriage in adults (11, 12). However,
the 2013 recommendations were based on carriage studies using culture-based meth-
odology, where the sensitivity of sampling the nasopharynx alone ranged between
58% and 81% compared with sampling both sites. The WHO highlighted that further
research was needed to ascertain whether this recommendation is appropriate when
using molecular techniques, which are becoming more common globally (11). More
recently, two studies have compared NP and OP sampling in adults and adolescents for
the detection of pneumococci using molecular methods (17, 18). Both studies con-
cluded that sampling the oropharynx was superior to sampling the nasopharynx. A
recent review examining studies of upper respiratory tract carriage of S. pneumoniae in
adults, including those that utilized molecular methods, also encourages the sampling
of other respiratory sites, such as OP and/or saliva, in addition to NP sampling (19).
However, there is some evidence that the use of molecular methods, particularly for
serotyping of S. pneumoniae in OP samples, may yield false-positive results (20, 21). This
may be particularly problematic in serotyping of S. pneumoniae in OP samples due to
the presence of capsule biosynthesis genes in nonpneumococcal species similar to
pneumococcal capsule loci. In this study, we examined whether molecular methods can
be used to accurately identify and serotype pneumococci in adult OP samples. To do
this, we used molecular methods for identification and serotyping on 250 paired adult
NP and OP swabs collected as part of a vaccine evaluation study in Fiji (22). We assessed
whether the use of multiple quantitative PCR (qPCR) targets could improve molecular
detection of pneumococci from OP samples, and investigated how the presence of
nonpneumococcal streptococci may confound molecular detection and serotyping of
pneumococci.
RESULTS AND DISCUSSION
The aim of our study was to examine the performance of molecular methods for
identification and serotyping of pneumococci in adult OP samples. To do this, we
evaluated the detection of pneumococci applying molecular methods to 250 paired NP
and OP samples, collected from the same participant but stored and processed
individually. A subset of OP samples and isolates was further explored to investigate
potential false-positive results caused by nonpneumococcal streptococci.
S. pneumoniae identification in NP and OP samples. Samples were initially
screened for pneumococci using DNA extracted directly from skim milk-tryptone-
glucose-glycerol (STGG) medium using lytA qPCR, with samples classified as positive
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(cycle threshold value [CT],35), equivocal (CT, 35 to 40), or negative (no CT) (Table 1).
Forty-three (17%) of the 250 OP samples screened were either lytA positive (9/250 [4%])
or equivocal (34/250 [14%]), while 33 (13%) of the 250 NP samples tested were either
lytA positive (14/250 [6%]) or equivocal (19/250 [8%]). All lytA-positive and equivocal
samples were tested for the presence of pneumococci using DNA microarray following
culture enrichment on selective agar (23).
For NP samples, microarray detected pneumococci in 13/14 (93%) lytA-positive
samples and 7/19 (37%) lytA-equivocal samples. In contrast, microarray detected pneu-
mococci in 7/9 (78%) lytA-positive OP samples, compared with only 3/34 (9%) lytA-
equivocal OP samples. The proportion of lytA-equivocal samples that were found to be
true positives for pneumococci was higher for NP samples than for OP samples
(P 0.025), suggesting that the lytA gene is a poor target for the detection of
pneumococci in adult OP samples. Our findings are consistent with a study examining
carriage in Kenyan adults using 40 combined NP/OP samples, in which the real-time
lytA PCR positivity rate (60%) was much higher than what could be confirmed using
culture (12.5%) (20).
When cultured on selective media, OP samples typically produced a greater diversity
of colony morphologies (and therefore may be more likely to contain a number of
different gentamicin-resistant species [see Fig. S1 in the supplemental material]) than
NP samples. Consistent with this, pneumococci were only detected by microarray in
10/42 (24%) of OP samples that had bacterial growth on gHBA (horse blood agar plates
containing 5 g/ml of gentamicin) plates, compared with 20/20 (100%) NP samples
(two additional NP samples were not tested by microarray, as they lacked -hemolytic
growth). OP samples also had a greater density of bacterial growth on gHBA plates than
NP samples: 41/42 (98%) of OP samples had growth on a 1:100 dilution plate, compared
with 13/22 (59%) of NP samples (P 0.001), consistent with a study with Dutch adults
(17).
OP sample characterization. We hypothesized that the presence of nonpneumo-
coccal streptococci in the oropharynx may contribute to the lytA signal and may lead
to false identification of pneumococci. We therefore sought to confirm the presence of
nonpneumococcal streptococci using microarray which, though not designed specifi-
cally for identification of individual streptococci, can confirm the presence of strepto-
coccal species. We tested 30 OP samples using microarray (5 of which were lytA positive
and 25 lytA equivocal) and found that while only 5 (17%) contained pneumococci, all
contained complex mixtures of nonpneumococcal species, including Streptococcus
salivarius, Streptococcus mitis, Streptococcus oralis, Streptococcus infantis, and, less com-
monly, Streptococcus parasanguinis, Streptococcus anginosus, and Streptococcus sangui-
nis. The detection of streptococci by microarray also suggests that the reasons for
TABLE 1 Pneumococcal carriage results obtained from paired nasopharyngeal and
oropharyngeal swabsa
lytA qPCR result Microarray result
NPb samples
(n 250)
OPc samples
(n 250)
Positive (CT, 35) Positive 13 7
Negative 0 2
No growthd 1 0
Equivocal (CT, 35–40) Positive 7 3
Negative 0 30
No growthe 12 1
Negative (no CT) 217 207
aSamples were screened by lytA quantitative real-time PCR, and positive and equivocal samples were further
tested by culture on selective agar and DNA microarray.
bNP, nasopharyngeal.
cOP, oropharyngeal.
dOne NP sample was nonculturable and therefore not tested by microarray.
eEquivocal samples with no growth were considered negative for pneumococci (54).
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discrepancies between lytA qPCR and microarray in pneumococcal detection are not
due to poor sensitivity of microarray. While S. pneumoniae has distinct lytA alleles
compared with the mitis group, there is evidence that lytA qPCR can both misidentify
commensal streptococci as pneumococci and fail to identify pneumococci (24, 25).
Genetic exchange with streptococci has played a major role in evolution of S. pneu-
moniae, and many S. pneumoniae virulence genes are also present in S. mitis, S. oralis,
and S. infantis (26). As bacterial diversity in the oropharynx is higher than in the
nasopharynx (27), there is greater opportunity for genetic exchange between strepto-
cocci. This genetic exchange, particularly within members of the mitis group strepto-
cocci, means that the reliance on one single loci for identification may result in
erroneous species identification (28).
Alternative qPCR-based S. pneumoniae identification in OP samples. Next, we
aimed to improve qPCR-based identification of pneumococci in OP samples by evalu-
ating alternative target genes, which could be potentially used alone or in combination
with lytA. We assessed the seven potential targets (Tables S2 and S3) by conventional
and real-time PCR against a set of 30 reference isolates (6 S. pneumoniae and 24
nonpneumococcal streptococcal isolates) (Tables S4 and S5). Based upon the results,
the genes bguR and piaB were further tested.
The bguR and piaB qPCR assays were applied to DNA extracted from 250 OP
samples, which had been previously tested with lytA qPCR. One hundred forty-two
samples were negative for all three targets. One hundred eight samples were positive
or equivocal for either bguR, piaB, and/or lytA and were subsequently cultured on gHBA
plates and analyzed by microarray. Based on microarray results, the gold standard for
pneumococcal identification in our study by detection of multiple species-specific
genes, 11 (10%) out of 108 samples contained S. pneumoniae. Note that the matched
NP sample was also positive for pneumococci for two of these 11 OP samples;
therefore, by using OP samples, nine additional pneumococcal carriers were detected.
The three qPCR targets were evaluated for sensitivity, positive predictive value (PPV),
and specificity individually and in combination using a CT of 40 as a cutoff for
positivity (Table 2).
Individually, none of the targets performed well: piaB had 33% PPV and 92%
specificity, lytA had 26% PPV and 88% specificity, and bguR had 13% PPV and 72%
specificity. All three targets had one false negative (to give a sensitivity of 91%). When
two targets were combined, the PPV and specificity improved (ranging from 42 to 47%
and 94 to 96%, respectively), although when piaBwas used with lytA or bguR there were
two false negatives, reducing the sensitivity of these combinations to 82%. Combining
all three targets further improved both PPV (53%) and specificity (97%) but yielded
lower sensitivity (82%) than for single targets. It should be noted that the PPV of all
approaches and the specificity of most approaches investigated were inferior to the use
of lytA in NP samples (64% PPV and 95% specificity). Our findings were in contrast to
those of a recent study exploring the use of lytA, piaB, and SP2020 (bguR) assays for the
detection of pneumococci (29). When tested on 80 OP samples, there were few
inconsistencies between assays and no apparent issues with the lytA assay, and
TABLE 2 Evaluation of lytA, bguR, and piaB qPCR (alone and in combination) for detection of pneumococci in 250 OP samplesa
Target gene(s)
No. of:
True positives False positives False negatives True negatives PPV (%)b Specificity (%) Sensitivity (%)
lytA 10 29 1 210 26 88 91
bguR 10 68 1 171 13 72 91
piaB 10 20 1 219 33 92 91
lytA  bguR 10 14 1 225 42 94 91
lytA  piaB 9 11 2 228 45 95 82
bguR  piaB 9 10 2 229 47 96 82
lytA  bguR  piaB 9 8 2 231 53 97 82
aA positive is defined as any CT of 40.
bPositive predictive value (PPV), specificity, and sensitivity were compared to DNA microarray, the study gold standard for pneumococcus-positive samples.
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combining assays eliminated false positives. The reasons for the discrepancies between
studies is unclear.
The primary aim of this study was to evaluate targets for use in a screening assay,
and therefore, we focused primarily on specificity and PPV. Any sample that was
negative by all three targets was deemed a true negative. For each individual assay,
there was a subset of samples that were negative for that assay and were tested further
(69, 30, and 78 for lytA, bguR, and piaB, respectively). However, one limitation of our
study is that we lacked a complete measure of false negatives and therefore did not
fully evaluate sensitivity and negative predictive value.
If these assays were used for identification rather than detection of pneumococcus-
positive adult OP samples, a more stringent cutoff would be more appropriate. When
we applied a cutoff CT of 35 to our OP samples, lytA was the best target (99%
specificity, 78% PPV, and 64% sensitivity) and the use of multiple targets was not
appropriate (all other target/s had 36% sensitivity) (Table S6). We also considered a
sequential screening approach whereby only those samples with a CT of 40 for one
target would be further tested by other targets, which gave 37 to 41% PPV, 93 to 95%
specificity, and 82 to 91% sensitivity (Table S7). We also explored the possibility that
false-positive samples could be identified through differences in signal intensity be-
tween two targets; however, no clear differences were observed in positive samples
versus negative samples for any target combination. Although we had only a small
number of pneumococcus-positive OP samples, our results indicate that qPCR may be
unreliable for accurate detection of pneumococci in OP samples even when multiple
targets are used.
S. pneumoniae serotyping in NP and OP samples. Next, we conducted molecular
serotyping of pneumococci from NP and OP samples using DNA microarray. The
microarray detects multiple targets for each of the pneumococcal capsule genes in
order to assign a serotype, and it is the best method for detecting multiple serotypes
in NP samples from children owing to its high sensitivity and PPV (95.8% and 93.9%,
respectively) (23). Serotyping of NP samples from adults using microarray was relatively
straightforward (Fig. 1a), with only one (18/20 [90%]) or two (2/20 [10%]) serotypes
detected in each sample. Additionally, all samples were clearly positive for pneumo-
cocci and no other streptococci were detected.
In contrast, OP samples were highly complex and challenging to serotype, with the
presence of partial or divergent sets of capsule genes that were likely to be present in
nonpneumococcal species, here referred to as pseudoserotypes. Serotyping was at-
tempted on 108 OP samples, with a total of 876 serotypes (n 20) and pseudosero-
types (n 856) detected (Fig. 1b and c). Only one OP sample had no growth on blood
agar plates and was therefore unable to be further tested. Of the 107 OP samples, 55
(51%) had 10 serotypes and/or pseudoserotypes detected, only 5 samples had no
serotypes or pseudoserotypes (streptococci were detected in all 5, so this was not due
to an error in the microarray) and no OP samples had only pneumococci and pneu-
mococcal serotypes. The most common pseudoserotype was similar to serotype 36
(“36-like,” indicating that a partial or divergent set of serotype 36 pneumococcal
capsule genes was detected) and was present in 83% (89/107) of OP samples.
Additional characterization of OP samples. We next investigated whether the
presence of pseudoserotypes in nonpneumococcal streptococci in the OP samples
could lead to false-positive serotyping results using other methods, and/or potentially
produce capsule similar to true pneumococci. We selected 11 OP samples for this
detailed analysis, representing a variety of their prior lytA qPCR and microarray sero-
typing results. For example, two samples were lytA positive but had no pneumococci
detected by microarray, while another had a complete (or near complete) set of capsule
genes for serotype 9V but had no pneumococci detected. Only 2 of the 11 samples
were found to contain pneumococci using microarray. We tested the 11 OP samples
with antibody-based and molecular-based serotyping methods (latex sweep aggluti-
nation and multiplex PCR [mPCR], respectively) (Table 3). When latex sweep aggluti-
Oropharyngeal Samples for Adult Pneumococcal Carriage
July/August 2020 Volume 5 Issue 4 e00478-20 msphere.asm.org 5
 o
n
 August 7, 2020 by guest
http://m
sphere.asm
.org/
D
ow
nloaded from
 
nation was used, 6 of 11 samples had a serotype detected. For mPCR, all 11 samples had
a serotype detected; however, for 2 samples, the cpsA pneumococcal control gene was
absent. While all three methods (microarray, latex sweep agglutination and mPCR)
detected pseudoserotypes, only microarray designated these as coming from nonpneu-
mococcal species.
OP isolate characterization. We recultured these 11 OP samples on gHBA plates
and isolated a representative of each colony morphology identified in the sample
(n 5 for each sample). The resultant 91 isolates from these 11 OP samples were
further characterized by the identification tests lytA, bguR and piaB real-time PCR,
optochin susceptibility, bile solubility, and matrix-assisted laser desorption ionization–
time of flight mass spectrometry (MALDI-TOF MS), as well as latex agglutination for
serotyping (Table S8 and S9). An isolate was deemed S. pneumoniae if at least three out
of four identification tests were indicative of S. pneumoniae; if only two tests were
indicative of S. pneumoniae, DNA microarray was used to resolve identification. Only
three of these isolates were identified as S. pneumoniae. Nearly half (41/88 [47%]) of the
nonpneumococcal isolates were identified as S. mitis/S. oralis (not distinguished by
MALDI-TOF MS), with S. parasanguinis (12/88 [14%]) and S. salivarius (11/88 [13%]) also
common (Fig. 2a). For 11 of the 88 isolates, no identification was obtained by MALDI-
TOF MS.
Serotyping by latex agglutination was attempted on all 91 isolates; however, 33
isolates did not emulsify in saline and so were not able to be tested. We did not identify
FIG 1 (a) Frequency of pneumococcal serotypes detected in NP samples. (b and c) Pneumococcal capsular genes
detected in OP samples from S. pneumoniae (serotypes) (b) or other species (pseudoserotypes) (c). *, others include
9V, 9L, 18A-like, 18C-like, 20-like, 33F-like, 37, 41F-like, 47A, NT3a, and NT4a (all n 2) and 1, 41A, 7A-like, 7F, 9A,
9N-like, 10F, 13-like, 17A-like, 17-like, 20A, 22A, 24B-like, 28A-like, 32F-like, 33B-like, 35B, 35F-like, 40, 41A-like, 46,
and 48 (all n 1).
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a serotype for 45 isolates. A serotyping result was obtained for 10 of 55 nonpneumo-
coccal isolates, with results shown in Fig. 2b. When the 10 isolates were serotyped by
Quellung, none were positive, although some slight cell enlargement was observed for
some isolates. The reasons for this were not explored, but it is plausible that the capsule
FIG 2 MALDI-TOF MS identification (a), latex agglutination (b), and microarray serotyping (c) results for
88 nonpneumococcal isolates subcultured from 11 OP samples. These data do not include results from
33 isolates that were not able to be tested by latex agglutination or from 47 isolates that were not tested
by microarray for practical reasons.
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polysaccharide produced may be thinner in these closely related species than pneu-
mococcal capsule polysaccharide, or not covalently linked to the cell wall peptidogly-
can, therefore making it difficult to observe the typical “swelling” in a Quellung
reaction.
To further elucidate the source of the spurious identification and serotyping results,
a subset of isolates (n 41) were serotyped by microarray. These included all isolates
that were equivocal for lytA and positive for a serotype/serogroup in latex agglutination
and at least one isolate for each unique MALDI-TOF MS result. Pseudoserotypes were
detected for 38 of the 41 (93%) nonpneumococcal isolates tested, with results shown
in Fig. 2c. We conducted whole-genome sequencing on two of the nonpneumococcal
OP isolates (which had typed as 19B [n 1] or 33F [n 1] by latex agglutination) and
compared the cps locus of these isolates with the cps locus of a corresponding true
pneumococcal serotype. Isolate FVEP-002-080-02 (which serotyped as 19B by latex
agglutination) was identified as S. infantis and had a full set of 19B capsule genes,
although the first six genes shared78% identity with the 19B reference isolate
(Fig. 3a). Isolate FVEP-002-002-03, which serotyped as 33F using latex agglutination,
was identified as Streptococcus oralis subsp. tigurinus (Fig. 3b). The cps region of this
isolate was similar to that of 33F; however, two copies of wzx were present (one of
which was truncated). A wcrG gene, which is normally found in serotype 10A, was also
present. Excluding the truncated wzx gene and the wcrG gene, this cps locus was highly
similar to the S. oralis subsp. tigurinus strain Az_3a cps locus (30), including the presence
of the wcyO gene (which is most similar to that of serotype 21 and is not typically
present in serotype 33F pneumococci).
General discussion. Our findings from testing the isolates confirm that the non-
pneumococcal streptococci in OP samples can contribute to false positives for pneu-
mococcal serotyping. Pseudoserotypes were found in all of the 38 nonpneumococcal
streptococci isolates tested. Importantly, our results suggest that nonpneumococcal
streptococci present in the oropharynx may be falsely identified as pneumococci and
FIG 3 Comparison of the capsule gene locus for isolate FVEP-002-080-02 (a) with serotype 19B (GenBank accession no. CR931676.1) and the capsule gene locus
for isolate FVEP-002-002-03 (b) with serotype 33F (GenBank accession no. AJ006986.1). Sequence identity (percent) between the two sets of genes is shown.
Genes are categorized according to characteristics used by Bentley et al. (53). Green boxes around genes indicate that a gene was categorized as present by
microarray serotyping.
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can also produce capsule similar to pneumococcal capsule. Consistent with this, several
recent studies have reported closely related streptococci expressing capsular polysac-
charide antigenically similar to pneumococcal capsule (30–32). Kilian et al. have sug-
gested that the diversity of the cps locus emerged from unidirectional interspecies gene
transfer from commensal streptococci to S. pneumoniae (33, 34). Recently, Streptococcus
mitis strains that produce capsule immunologically consistent with pneumococcal
serotype 1 have recently been reported (35), raising questions as to whether carriage
of such strains would induce an immune response to pneumococci.
A key strength of our study was applying some of the best available methods for
serotyping our OP samples. The use of multiple different methods also allowed us to
demonstrate that specificity issues affect multiple types of serotyping methods and are
not limited to one method alone. Samples were processed in batches that included
both NP and OP samples and multiple extraction controls, thereby eliminating the
possibility that underlying differences have emerged due to contamination or batch
variability. A limitation of our study is that we used a culture enrichment step prior to
pneumococcal identification using microarray, and it is possible that we may have
missed some samples containing pneumococci. We chose microarray as a gold stan-
dard for pneumococcal identification in this study because it is not based on one single
data point or gene sequence but includes targets over the entire genome, which
provides greater confidence in results. It is plausible the presence of high-density
nonpneumococcal species on culture plates for OP samples may mask the detection of
pneumococci in downstream testing, or some pneumococci may be nonviable. How-
ever, Trzcinski et al. found that culture enrichment improved detection of pneumococci
(17), and our overall findings are consistent with other studies which have shown the
presence of pneumococcal gene homologs in other closely related streptococci (20, 21,
36). Despite our detailed investigation, we were also unable to definitively identify the
source of spurious pneumococcal identification results. While we failed to find any
nonpneumococcal isolate that was positive for the lytA gene, we did find 10 isolates
which had some amplification. It is plausible that we may have missed those colonies
which directly contributed to the lytA result. It is also possible that, cumulatively, the
weak amplification in individual nonpneumococcal colonies contributes to equivocal
results at a sample level.
We should also note that our adult participants were mostly female (93%) and under
the age of 65 (98%) and therefore may differ from adult participants described in
studies aimed at understanding disease in older adults.
Taken together, our results highlight the challenging nature of conducting a pneu-
mococcal carriage study in adults using OP samples. The presence of other commensal
streptococci in the oropharynx interferes with identification and serotyping of true
pneumococci within an OP sample, regardless of whether culture-based or molecular
serotyping methods are used. For adult pneumococcal carriage studies, approaches
which utilize multiple targets or loci, or involve the isolation and careful identification
of pneumococci, are necessary if OP samples are to be included, although the latter
may be impractical for a large study.
Given the challenges of identifying and serotyping pneumococci using OP samples
from adults, we caution against their routine use in carriage studies.
MATERIALS AND METHODS
Swab collection, transport, and storage. An NP and OP swab were collected from 250 adult
caregivers of children (adult caregivers) in 2012 as part of the Fiji New Vaccine Evaluation Project,
described previously (22); see Table S1 for study participant characteristics. In brief, NP and OP specimens
were collected concurrently by the same personnel using flocked nylon swabs (11, 12) and were
otherwise handled in the same manner. Each swab was placed in 1 ml of skim milk-tryptone-glucose-
glycerol (STGG) medium in an individual cryovial and transported in a cool box to the Fiji Centre for
Communicable Disease Control in Suva, Fiji. On arrival at the laboratory, swabs were vortexed for 20 s
prior to aliquoting and storage at 80°C within 8 h of collection, in line with WHO guidelines (11).
Samples were shipped on dry ice to the Murdoch Children’s Research Institute in Melbourne, Australia,
and stored at 80°C. For clarity, a flowchart showing the full set of experimental procedures conducted
on OP samples and the derived isolates is presented in Fig. 4.
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DNA extraction from swab samples. DNA was extracted from 100 l of STGG sample as previously
described (22). Each extraction run contained approximately equal numbers of NP and OP samples and
included STGG extraction controls that were checked for pneumococcal contamination using lytA qPCR.
qPCR on swab samples. The detection of S. pneumoniae by qPCR assays was performed on NP or
OP swabs using DNA extracted as described above. Assays targeting the lytA and piaB genes were
conducted as previously described (17, 37). An assay for the GntR-type transcriptional regulator gene
bguR (38) (TIGR4 NCBI reference sequence, NC_003028; locus tag, SP_RS10220; old locus tag, SP_2020),
also referred to as SP2020 (19, 29), used forward primer (5=-AGTTTGCCTGTAGTCGAATGA-3=), reverse
primer (5=-TTTGAGCTGCCACGAGAG-3=) and the probe (5=-6-carboxyfluorescein [FAM]-AAACGTGGGCAG
GGAACCTTTGTT-BHQ1-3=) concentrations of 300 nM, 100 nM, and 200 nM, respectively. No-template
controls (blanks) were included in each qPCR run, and runs were balanced with approximately equal
numbers of NP and OP samples. Samples were considered positive when the cycle threshold value (CT)
was35, equivocal when the CT was between 35 and 40, and negative when no CT value was obtained
in 40 cycles.
Pneumococcal identification and molecular serotyping by DNA microarray. Samples that were
either positive or equivocal for the lytA, piaB, or bguR gene were cultured for microarray analysis. Samples
were analyzed by a pneumococcal molecular serotyping microarray (Senti-SP1.4/1.5; BUGS Bioscience) as
previously described (23). Microarray analysis was performed following culture amplification on horse
blood agar plates containing 5 g/ml of gentamicin (gHBA; Oxoid brand, Thermo Fisher Scientific,
Australia), and DNA extraction (for gHBA plates with -hemolytic growth only) using the QIAamp 96 DNA
QIAcube HT kit (Qiagen) or the QIAamp DNA minikit (Qiagen).
Alternative S. pneumoniae target genes. We considered alternative target genes to lytA for the
detection of S. pneumoniae. Fifteen targets identified by a literature search and/or used in the S.
pneumoniae StrepID component of the microarray were initially considered. We excluded 4 targets (rpoA,
sodA, tuf, and recA) because they required sequencing of the PCR product and 4 targets (ply, psaA,
spn9802, and 16S rRNA genes) because they have been reported to lack the specificity to distinguish
between closely related species or the sensitivity to detect all pneumococci. Genes piaA, piaB, and ulaA
FIG 4 Experimental procedures for OP samples and isolates. gHBA, gentamicin horse blood agar.
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were selected for further analysis as well as four additional genes used in the StrepID component of
microarray (see Table S2 and S3). Targets were tested against a set of 30 reference isolates (6 S.
pneumoniae and 24 nonpneumococcal streptococcal isolates) initially by PCR assays (see Table S4).
Real-time qPCR assays for lytA, piaB, and bguR (described above) were also assessed against the reference
isolates (see Table S5).
Isolation of bacteria from OP samples. Samples were cultured directly on gHBA, and a repre-
sentative of each colony morphology (including nonhemolytic and -hemolytic colonies) for each
sample was then subcultured onto HBA and incubated overnight (37°C, 5% CO2) with an optochin
disc. All OP isolates (n 91) were then tested for bile solubility (39). A laboratory strain of S.
pneumoniae (PMP6, ATCC 6305) and S. mitis (PMP16) were used as controls for optochin sensitivity
and bile solubility testing.
DNA extraction on isolates. A sweep of pure culture was inoculated into 100 l of phosphate-
buffered saline using a 10-l sterile loop. Bacterial suspensions were pelleted at 7,380 g for 10 min.
Initially, DNA was extracted from all OP isolates using the QIAcube HT instrument (Qiagen). Prior to
loading the instrument, pellets were resuspended in lysis buffer (20 mM Tris-HCl, 2 mM Na-EDTA, 1%
[vol/vol] Triton X-100, 2 mg/ml of RNase A, and 20 mg/ml lysozyme) and incubated at 37°C for 60 min.
Twenty microliters of 20-mg/ml proteinase K (Qiagen) and 200 l of buffer AL (Qiagen) were added
before incubation at 56°C for a further 30 min.
However, for many of the isolates (n 52) there were issues during the extraction process resulting
in poor-quality DNA. These isolates were extracted using the QIAamp DNA minikit (Qiagen) as described
previously (40), with the following modifications: prior to the addition of the enzymatic lysis buffer,
samples underwent a freeze-thaw step at –80°C for 15 min, and DNA was eluted in 100 l of nuclease-
free H2O (Ambion), with two elution steps of 50 l each.
Real-time PCR on isolates. Real-time PCR assays were performed on isolate DNA normalized to a
concentration of 1 ng/l. Real-time PCR assays targeting the lytA, piaB, and bguR genes were performed
using the same conditions and primer and probe concentrations as the qPCR assays. Isolates were
considered positive when the CTwas 30.
MALDI-TOF MS. All OP isolates were identified by MALDI-TOF MS using the Vitek MS (bioMérieux)
system according to the manufacturer’s instructions. Following an overnight culture of the isolates on
HBA, approximately four colonies (i.e., a visible amount of bacterial growth) were applied to the Vitek
MS-DS target slide (bioMérieux) using a sterile toothpick. Immediately after application to the slide, 1 l
of Vitek MS-CHCA matrix solution (bioMérieux) was added to the bacteria on the slide. After allowing the
matrix solution to air dry, the slide was loaded into the Vitek MS machine. Following run completion,
results were analyzed using MYLA software (version 4; bioMérieux).
S. pneumoniae isolate identification. An isolate was identified as S. pneumoniae if at least three of
the following results were obtained: optochin sensitivity, bile solubility, a MALDI-TOF MS result of S.
pneumoniae, and lytA real-time PCR positivity. Where only two of the four tests were indicative of S.
pneumoniae, the StrepID component of microarray, based on detection of species-specific genes, was
used to discriminate between S. pneumoniae and non-S. pneumoniae. Where none or one of the tests was
indicative of S. pneumoniae, an isolate was considered non-S. pneumoniae.
Serotyping by latex agglutination and Quellung reaction. Latex agglutination was performed
using reagents produced in-house (41) with Statens Serum Institute (SSI) antisera on a sweep of growth
from the sample culture plate (latex sweep) or an isolate (latex agglutination) (39, 55). Quellung testing
was performed as previously described (42) using SSI antisera on isolates for which pneumococcal
serotypes were detected using latex agglutination. Reactions were visualized using a microscope at a
magnification of 400.
Serotyping by mPCR. Serotyping multiplex PCR (mPCR) was performed using the method described
by Carvalho et al. (43) and on the Centers for Disease Control and Prevention (CDC) Streptococcus
Laboratory PCR Deduction of Pneumococcal Serotypes website (https://www.cdc.gov/streplab/pcr.html;
accessed 14 July 2015) using 5 ng/l of template DNA. PCR products were examined for size using an
Agilent 2100 Bioanalyzer instrument (Agilent Technologies) and also run on an E-Gel 48 2% agarose gel
(Invitrogen) according to the manufacturer’s instructions. Results from both the E-Gel and Bioanalyzer
methods were compared, and only products detected by both methods were considered true products.
Products within 30 bp of an expected serotype product size were considered positive for the serotype.
Whole-genome sequencing. Two isolates which were not pneumococcus but yielded a pneumo-
coccal serotype (using both latex agglutination and microarray) underwent whole-genome sequencing
to identify any pneumococcal-like cps regions. Isolates FVEP-002-002-03 and FVEP-002-080-02 were
sequenced using Illumina MiSeq V2 reagent kits (2 150 bp) on the MiSeq platform (Illumina). Sequence
reads were down-sampled so that the assemblies would have approximately 150 coverage. Sequence
assembly was performed using SPAdes version 3.5.0 (44). Assembled contigs were then submitted to the
RAST server for annotation (45). Species identification was done using a combination of MetaPhlAN v2.0 (46),
Kraken (47), and eMLSA (48), plus using 16S sequences from the isolates with 16S SILVA Incremental Aligner
(SINA) version 1.2.11 (49), Greengenes BLAST (50), and NCBI BLAST (51). Capsule genes were identified
following RAST annotation and were aligned against 33F and 19B reference sequences (GenBank accession
numbers AJ006986.1 and CR931676.1, respectively); sequences that aligned poorly were checked by NCBI
BLAST. Figures for aligned sequences were generated using easyfig version 2.2.2 (52).
Data analysis. Data were analyzed and graphs were generated using GraphPad Prism version
7.02 and R version 3.2.4. A P value of 0.05 was considered statistically significant. For differences
in categorical data, Fisher’s exact test was used. When evaluating qPCR assays (alone or in
combination), samples found to contain pneumococci following culture amplification and DNA
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microarray were considered true positives. The sensitivity, specificity, and positive predictive value
(PPV) of assays were determined.
Data availability. The bacterial genomes for FVEP-002-002-03 and FVEP-002-080-02 analyzed
during the current study are available in the NCBI Sequence Read Archive under accession number
PRJNA590329 (https://www.ncbi.nlm.nih.gov/bioproject/590329). Other data and materials used are
available upon reasonable request but may require ethical approval from the Fiji National Health
Research and Ethics Review Committee and the University of Melbourne Health Sciences Human Ethics
Subcommittee.
SUPPLEMENTAL MATERIAL
Supplemental material is available online only.
FIG S1, DOCX file, 0.7 MB.
TABLE S1, DOCX file, 0.01 MB.
TABLE S2, DOCX file, 0.02 MB.
TABLE S3, DOCX file, 0.01 MB.
TABLE S4, DOCX file, 0.02 MB.
TABLE S5, DOCX file, 0.02 MB.
TABLE S6, DOCX file, 0.01 MB.
TABLE S7, DOCX file, 0.01 MB.
TABLE S8, DOCX file, 0.01 MB.
TABLE S9, DOCX file, 0.04 MB.
ACKNOWLEDGMENTS
We thank the study participants and their families and the staff involved in the New
Vaccine Evaluation Project in Fiji. We thank scientists from the Microbiological Diag-
nostic Unit—Public Health Laboratory, Department of Microbiology and Immunology,
The University of Melbourne at the Peter Doherty Institute for Infection and Immunity,
Melbourne, for the MALDI-TOF MS used for species identification. We thank Ahmed
Alamrousi for assistance with laboratory testing and Stephanie Eggers from the Trans-
lational Genomics Unit at Murdoch Children’s Research Institute for the whole-genome
sequencing. We also thank Fuminori Sakai from Emory University for kindly providing
streptococcal isolates for the reference set.
F.M.R. and E.K.M. oversaw and F.T.R. led the field work for the New Vaccine
Evaluation Project in Fiji. C.S. oversaw the current study, with J.H. and E.M.D. L.K.B.,
E.M.D., K.A.G., J.H., J.E.V., and C.S. conceived of and contributed to the design. L.K.B.
conducted laboratory analyses with K.A.G. L.K.B. wrote the manuscript with E.M.D. and
C.S. All authors read and approved the final manuscript.
Collection of the samples used in this research was funded through the New Vaccine
Evaluation Project in Fiji (funded through Bill & Melinda Gates Foundation [OPP126272
and OPP1084341] and the Department of Foreign Affairs and Trade of the Australian
Government and Fiji Health Sector Support Program [FHSSP]). L.K.B. was supported by a Fay
Marles Scholarship, The University of Melbourne. C.S. was supported by an Australian
NHMRC Career Development Fellowship (1087957) and a Veski Inspiring Women Fellow-
ship. F.M.R. is supported by an NHMRC early career and TRIP fellowship. J.E.V. was in part
supported by grants from the National Institutes of Health (NIH; R21AI112768-01A1 and
1R21AI144571-01). The Murdoch Children’s Research institute was supported by the Vic-
torian Government’s Operational Infrastructure Support Program.
C.S., E.M.D., and E.K.M. are investigators on an unrelated collaborative research
project funded by Pfizer. J.H. is an investigator on studies done on behalf of St George’s,
University of London, or BUGS Bioscience that are sponsored or funded by vaccine
manufacturers, including Pfizer, GlaxoSmithKline, and Sanofi Pasteur. All other authors
declare no competing interests.
REFERENCES
1. O’Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, Lee E,
Mulholland K, Levine OS, Cherian T, Hib and Pneumococcal Global Burden
of Disease Study Team. 2009. Burden of disease caused by Streptococcus
pneumoniae in children younger than 5 years: global estimates. Lancet
374:893–902. https://doi.org/10.1016/S0140-6736(09)61204-6.
2. Drijkoningen JJC, Rohde G. 2014. Pneumococcal infection in adults:
Oropharyngeal Samples for Adult Pneumococcal Carriage
July/August 2020 Volume 5 Issue 4 e00478-20 msphere.asm.org 13
 o
n
 August 7, 2020 by guest
http://m
sphere.asm
.org/
D
ow
nloaded from
 
burden of disease. Clin Microbiol Infect 20(Suppl 5):45–51. https://doi
.org/10.1111/1469-0691.12461.
3. Bogaert D, De Groot R, Hermans P. 2004. Streptococcus pneumoniae
colonisation: the key to pneumococcal disease. Lancet Infect Dis
4:144–154. https://doi.org/10.1016/S1473-3099(04)00938-7.
4. Simell B, Auranen K, Käyhty H, Goldblatt D, Dagan R, O’Brien KL, Pneu-
mococcal Carriage Group. 2012. The fundamental link between pneu-
mococcal carriage and disease. Expert Rev Vaccines 11:841–855. https://
doi.org/10.1586/erv.12.53.
5. Cohen R, Cohen JF, Chalumeau M, Levy C. 2017. Impact of pneumococ-
cal conjugate vaccines for children in high- and non–high-income coun-
tries. Expert Rev Vaccines 16:625–640. https://doi.org/10.1080/14760584
.2017.1320221.
6. Feikin DR, Kagucia EW, Loo JD, Link-Gelles R, Puhan MA, Cherian T,
Levine OS, Whitney CG, O’Brien KL, Moore MR, Serotype Replacement
Study Group. 2013. Serotype-specific changes in invasive pneumococcal
disease after pneumococcal conjugate vaccine introduction: a pooled
analysis of multiple surveillance sites. PLoS Med 10:e1001517. https://
doi.org/10.1371/journal.pmed.1001517.
7. Gladstone RA, Jefferies JM, Tocheva AS, Beard KR, Garley D, Chong WW,
Bentley SD, Faust SN, Clarke SC. 2015. Five winters of pneumococcal
serotype replacement in UK carriage following PCV introduction. Vac-
cine 33:2015–2021. https://doi.org/10.1016/j.vaccine.2015.03.012.
8. Tsaban G, Ben-Shimol S. 2017. Indirect (herd) protection, following
pneumococcal conjugated vaccines introduction: a systematic review of
the literature. Vaccine 35:2882–2891. https://doi.org/10.1016/j.vaccine
.2017.04.032.
9. Davis SM, Deloria-Knoll M, Kassa HT, O’Brien KL. 2013. Impact of pneumo-
coccal conjugate vaccines on nasopharyngeal carriage and invasive disease
among unvaccinated people: review of evidence on indirect effects. Vaccine
32:133–145. https://doi.org/10.1016/j.vaccine.2013.05.005.
10. Chan J, Nguyen CD, Dunne EM, Kim Mulholland E, Mungun T, Pomat WS,
Rafai E, Satzke C, Weinberger DM, Russell FM. 2019. Using pneumococcal
carriage studies to monitor vaccine impact in low- and middle-income
countries. Vaccine 37:6299–6309. https://doi.org/10.1016/j.vaccine.2019
.08.073.
11. Satzke C, Turner P, Virolainen-Julkunen A, Adrian PV, Antonio M, Hare
KM, Henao-Restrepo AM, Leach AJ, Klugman KP, Porter BD, Sá-Leão R,
Scott JA, Nohynek H, O’Brien KL, WHO Pneumococcal Carriage Working
Group. 2013. Standard method for detecting upper respiratory carriage
of Streptococcus pneumoniae: updated recommendations from the
World Health Organization Pneumococcal Carriage Working Group. Vac-
cine 32:165–179. https://doi.org/10.1016/j.vaccine.2013.08.062.
12. O’Brien KL, Nohynek H, WHO Pneumococcal Vaccine Trials Carriage Work-
ing Group. 2003. Report from a WHO working group: standard method for
detecting upper respiratory carriage of Streptococcus pneumoniae. Pediatr
Infect Dis J 22:e1–e11. https://doi.org/10.1097/01.inf.0000049347.42983.77.
13. Greenberg D, Broides A, Blancovich I, Peled N, Givon-Lavi N, Dagan R.
2004. Relative importance of nasopharyngeal versus oropharyngeal
sampling for isolation of Streptococcus pneumoniae and Haemophilus
influenzae from healthy and sick individuals varies with age. J Clin
Microbiol 42:4604–4609. https://doi.org/10.1128/JCM.42.10.4604-4609
.2004.
14. Watt JP, O’Brien KL, Katz S, Bronsdon MA, Elliott J, Dallas J, Perilla MJ,
Reid R, Murrow L, Facklam R, Santosham M, Whitney CG. 2004. Naso-
pharyngeal versus oropharyngeal sampling for detection of pneumo-
coccal carriage in adults. J Clin Microbiol 42:4974–4976. https://doi.org/
10.1128/JCM.42.11.4974-4976.2004.
15. Lieberman D, Shleyfer E, Castel H, Terry A, Harman-Boehm I, Delgado J,
Peled N, Lieberman D. 2006. Nasopharyngeal versus oropharyngeal
sampling for isolation of potential respiratory pathogens in adults. J Clin
Microbiol 44:525–528. https://doi.org/10.1128/JCM.44.2.525-528.2006.
16. Levine H, Zarka S, Dagan R, Sela T, Rozhavski V, Cohen DI, Balicer RD.
2012. Transmission of Streptococcus pneumoniae in adults may occur
through saliva. Epidemiol Infect 140:561–565. https://doi.org/10.1017/
S0950268811000884.
17. Trzcin´ski K, Bogaert D, Wyllie A, Chu M, van der Ende A, Bruin JP, van den
Dobbelsteen G, Veenhoven RH, Sanders E. 2013. Superiority of trans-oral
over trans-nasal sampling in detecting Streptococcus pneumoniae colo-
nization in adults. PLoS One 8:e60520. https://doi.org/10.1371/journal
.pone.0060520.
18. Principi N, Terranova L, Zampiero A, Manzoni F, Senatore L, Rios WP,
Esposito S. 2014. Oropharyngeal and nasopharyngeal sampling for the
detection of adolescent Streptococcus pneumoniae carriers. J Med Mi-
crobiol 63:393–398. https://doi.org/10.1099/jmm.0.068726-0.
19. Arguedas A, Trzcin´ski K, O’Brien KL, Ferreira DM, Wyllie AL, Weinberger
D, Danon L, Pelton SI, Azzari C, Hammitt LL, Sá-Leão R, Brandileone M-C,
Saha S, Suaya J, Isturiz R, Jodar L, Gessner BD. 2020. Upper respiratory
tract colonization with Streptococcus pneumoniae in adults. Expert Rev
Vaccines 19:353–366. https://doi.org/10.1080/14760584.2020.1750378.
20. Carvalho MDG, Pimenta FC, Moura I, Roundtree A, Gertz RE, Li Z, Jagero
G, Bigogo G, Junghae M, Conklin L, Feikin DR, Breiman RF, Whitney CG,
Beall BW. 2013. Non-pneumococcal mitis-group streptococci confound
detection of pneumococcal capsular serotype-specific loci in upper
respiratory tract. PeerJ 1:e97. https://doi.org/10.7717/peerj.97.
21. Carvalho MDG, Bigogo GM, Junghae M, Pimenta FC, Moura I, Roundtree
A, Li Z, Conklin L, Feikin DR, Breiman RF, Whitney CG, Beall B. 2012.
Potential nonpneumococcal confounding of PCR-based determination
of serotype in carriage. J Clin Microbiol 50:3146–3147. https://doi.org/
10.1128/JCM.01505-12.
22. Dunne EM, Satzke C, Ratu FT, Neal EFG, Boelsen LK, Matanitobua S, Pell
CL, Nation ML, Ortika BD, Reyburn R, Jenkins K, Nguyen C, Gould K, Hinds
J, Tikoduadua L, Kado J, Rafai E, Kama M, Mulholland EK, Russell FM.
2018. Effect of ten-valent pneumococcal conjugate vaccine introduction
on pneumococcal carriage in Fiji: results from four annual cross-
sectional carriage surveys. Lancet Glob Health 6:e1375–e1385. https://
doi.org/10.1016/S2214-109X(18)30383-8.
23. Satzke C, Dunne EM, Porter BD, Klugman KP, Mulholland EK, PneuCar-
riage project group. 2015. The PneuCarriage project: a multi-centre
comparative study to identify the best serotyping methods for examin-
ing pneumococcal carriage in vaccine evaluation studies. PLoS Med
12:e1001903. https://doi.org/10.1371/journal.pmed.1001903.
24. Llull D, López R, García E. 2006. Characteristic signatures of the lytA gene
provide a basis for rapid and reliable diagnosis of Streptococcus pneu-
moniae infections. J Clin Microbiol 44:1250–1256. https://doi.org/10
.1128/JCM.44.4.1250-1256.2006.
25. Simões AS, Tavares DA, Rolo D, Ardanuy C, Goossens H, Henriques-
Normark B, Linares J, de Lencastre H, Sá-Leão R. 2016. lytA-based iden-
tification methods can misidentify Streptococcus pneumoniae. Diagn
Microbiol Infect Dis 85:141–148. https://doi.org/10.1016/j.diagmicrobio
.2016.03.018.
26. Donati C, Hiller NL, Tettelin H, Muzzi A, Croucher NJ, Angiuoli SV,
Oggioni M, Dunning Hotopp JC, Hu FZ, Riley DR, Covacci A, Mitchell TJ,
Bentley SD, Kilian M, Ehrlich GD, Rappuoli R, Moxon ER, Masignani V.
2010. Structure and dynamics of the pan-genome of Streptococcus
pneumoniae and closely related species. Genome Biol 11:R107. https://
doi.org/10.1186/gb-2010-11-10-r107.
27. Stearns JC, Davidson CJ, McKeon S, Whelan FJ, Fontes ME, Schryvers AB,
Bowdish DME, Kellner JD, Surette MG. 2015. Culture and molecular-
based profiles show shifts in bacterial communities of the upper respi-
ratory tract that occur with age. ISME J 9:1246–1259. https://doi.org/10
.1038/ismej.2014.250.
28. Jensen A, Scholz CFP, Kilian M. 2016. Re-evaluation of the taxonomy of
the Mitis group of the genus Streptococcus based on whole genome
phylogenetic analyses, and proposed reclassification of Streptococcus
dentisani as Streptococcus oralis subsp. dentisani comb. nov., Streptococ-
cus tigurinus as Streptococcus oralis subsp. tigurinus comb. nov., and
Streptococcus oligofermentans as a later synonym of Streptococcus cris-
tatus. Int J Syst Evol Microbiol 66:4803–4820. https://doi.org/10.1099/
ijsem.0.001433.
29. Tavares DA, Handem S, Carvalho RJ, Paulo AC, de Lencastre H, Hinds J,
Sá-Leão R. 2019. Identification of Streptococcus pneumoniae by a real-
time PCR assay targeting SP2020. Sci Rep 9:3285. https://doi.org/10
.1038/s41598-019-39791-1.
30. Skov Sørensen UB, Yao K, Yang Y, Tettelin H, Kilian M. 2016. Capsular
polysaccharide expression in commensal Streptococcus species: genetic
and antigenic similarities to Streptococcus pneumoniae. mBio 7:e01844-16.
https://doi.org/10.1128/mBio.01844-16.
31. Sheppard CL, Kapatai G, Broughton K, Schaefer U, Hannah M, Litt DJ, Fry
NK. 2017. Clinical streptococcal isolates, distinct from Streptococcus
pneumoniae, but containing the -glucosyltransferase tts gene and
expressing serotype 37 capsular polysaccharide. PeerJ 5:e3571. https://
doi.org/10.7717/peerj.3571.
32. Pimenta F, Gertz RE, Park SH, Kim E, Moura I, Milucky J, Rouphael N,
Farley MM, Harrison LH, Bennett NM, Bigogo G, Feikin DR, Breiman R,
Lessa FC, Whitney CG, Rajam G, Schiffer J, da Gloria Carvalho M, Beall B.
2018. Streptococcus infantis, Streptococcus mitis, and Streptococcus oralis
Boelsen et al.
July/August 2020 Volume 5 Issue 4 e00478-20 msphere.asm.org 14
 o
n
 August 7, 2020 by guest
http://m
sphere.asm
.org/
D
ow
nloaded from
 
strains with highly similar cps5 loci and antigenic relatedness to serotype
5 pneumococci. Front Microbiol 9:3199. https://doi.org/10.3389/fmicb
.2018.03199.
33. Kilian M, Poulsen K, Blomqvist T, Håvarstein LS, Bek-Thomsen M, Tettelin
H, Sørensen U. 2008. Evolution of Streptococcus pneumoniae and its close
commensal relatives. PLoS One 3:e2683. https://doi.org/10.1371/journal
.pone.0002683.
34. Kilian M, Riley DR, Jensen A, Brüggemann H, Tettelin H. 2014. Parallel
evolution of Streptococcus pneumoniae and Streptococcus mitis to patho-
genic and mutualistic lifestyles. mBio 5:e01490-14. https://doi.org/10
.1128/mBio.01490-14.
35. Lessa FC, Milucky J, Rouphael NG, Bennett NM, Talbot HK, Harrison LH,
Farley MM, Walston J, Pimenta F, Gertz RE, Rajam G, Carvalho MDG, Beall
B, Whitney CG. 2018. Streptococcus mitis expressing pneumococcal se-
rotype 1 capsule. Sci Rep 8:17959. https://doi.org/10.1038/s41598-018
-35921-3.
36. Johnston C, Hinds J, Smith A, Van Der Linden M, Van Eldere J, Mitchell
TJ. 2010. Detection of large numbers of pneumococcal virulence genes
in streptococci of the mitis group. J Clin Microbiol 48:2762–2769. https://
doi.org/10.1128/JCM.01746-09.
37. Carvalho MDG, Tondella ML, McCaustland K, Weidlich L, McGee L, Mayer
LW, Steigerwalt A, Whaley M, Facklam RR, Fields B, Carlone G, Ades EW,
Dagan R, Sampson JS. 2007. Evaluation and improvement of real-time
PCR assays targeting lytA, ply, and psaA genes for detection of pneu-
mococcal DNA. J Clin Microbiol 45:2460–2466. https://doi.org/10.1128/
JCM.02498-06.
38. Shafeeq S, Kuipers OP, Kloosterman TG. 2013. Cellobiose-mediated gene
expression in Streptococcus pneumoniae: a repressor function of the
novel GntR-type regulator BguR. PLoS One 8:e57586. https://doi.org/10
.1371/journal.pone.0057586.
39. Castillo D, Harcourt B, Hatcher C, Jackson M, Katz L, Mair R, Mayer L,
Novak R, Rahalison L, Schmink S, Theodore MJ, Thomas J, Vuong J, Wang
X, McGee L. 2011. Laboratory methods for the diagnosis of meningitis
caused by Neisseria meningitidis, Streptococcus pneumoniae, and Haemo-
philus influenzae, 2nd ed. World Health Organization, Geneva, Switzer-
land.
40. Dunne EM, Manning J, Russell FM, Robins-Browne RM, Mulholland EK,
Satzke C. 2012. Effect of pneumococcal vaccination on nasopharyngeal
carriage of Streptococcus pneumoniae, Haemophilus influenzae, Moraxella
catarrhalis, and Staphylococcus aureus in Fijian children. J Clin Microbiol
50:1034–1038. https://doi.org/10.1128/JCM.06589-11.
41. Ortika BD, Habib M, Dunne EM, Porter BD, Satzke C. 2013. Production of
latex agglutination reagents for pneumococcal serotyping. BMC Res
Notes 6:49. https://doi.org/10.1186/1756-0500-6-49.
42. Habib M, Porter BD, Satzke C. 2014. Capsular serotyping of Streptococcus
pneumoniae using the Quellung reaction. J Vis Exp 84:e51208.
43. Carvalho MDG, Pimenta FC, Jackson D, Roundtree A, Ahmad Y, Millar EV,
O’Brien KL, Whitney CG, Cohen AL, Beall BW. 2010. Revisiting pneumo-
coccal carriage by use of broth enrichment and PCR techniques for
enhanced detection of carriage and serotypes. J Clin Microbiol 48:
1611–1618. https://doi.org/10.1128/JCM.02243-09.
44. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS,
Lesin VM, Nikolenko SI, Pham S, Prjibelski AD, Pyshkin AV, Sirotkin AV,
Vyahhi N, Tesler G, Alekseyev MA, Pevzner PA. 2012. SPAdes: a new
genome assembly algorithm and its applications to single-cell sequenc-
ing. J Comput Biol 19:455–477. https://doi.org/10.1089/cmb.2012.0021.
45. Aziz RK, Bartels D, Best AA, DeJongh M, Disz T, Edwards RA, Formsma K,
Gerdes S, Glass EM, Kubal M, Meyer F, Olsen GJ, Olson R, Osterman AL,
Overbeek RA, McNeil LK, Paarmann D, Paczian T, Parrello B, Pusch GD,
Reich C, Stevens R, Vassieva O, Vonstein V, Wilke A, Zagnitko O. 2008.
The RAST server: rapid annotations using subsystems technology. BMC
Genomics 9:75. https://doi.org/10.1186/1471-2164-9-75.
46. Segata N, Waldron L, Ballarini A, Narasimhan V, Jousson O, Huttenhower
C. 2012. Metagenomic microbial community profiling using unique
clade-specific marker genes. Nat Methods 9:811–814. https://doi.org/10
.1038/nmeth.2066.
47. Wood DE, Salzberg SL. 2014. Kraken: ultrafast metagenomic sequence
classification using exact alignments. Genome Biol 15:R46. https://doi
.org/10.1186/gb-2014-15-3-r46.
48. Bishop CJ, Aanensen DM, Jordan GE, Kilian M, Hanage WP, Spratt BG.
2009. Assigning strains to bacterial species via the internet. BMC Biol 7:3.
https://doi.org/10.1186/1741-7007-7-3.
49. Pruesse E, Peplies J, Glöckner FO. 2012. SINA: accurate high-throughput
multiple sequence alignment of ribosomal RNA genes. Bioinformatics
28:1823–1829. https://doi.org/10.1093/bioinformatics/bts252.
50. DeSantis TZ, Hugenholtz P, Larsen N, Rojas M, Brodie EL, Keller K, Huber
T, Dalevi D, Hu P, Andersen GL. 2006. Greengenes, a chimera-checked
16S rRNA gene database and workbench compatible with ARB. Appl
Environ Microbiol 72:5069–5072. https://doi.org/10.1128/AEM.03006-05.
51. Johnson M, Zaretskaya I, Raytselis Y, Merezhuk Y, McGinnis S, Madden
TL. 2008. NCBI BLAST: a better web interface. Nucleic Acids Res 36:
W5–W9. https://doi.org/10.1093/nar/gkn201.
52. Sullivan MJ, Petty NK, Beatson SA. 2011. Easyfig: a genome comparison
visualizer. Bioinformatics 27:1009–1010. https://doi.org/10.1093/bioinformatics/
btr039.
53. Bentley SD, Aanensen DM, Mavroidi A, Saunders D, Rabbinowitsch E, Collins
M, Donohoe K, Harris D, Murphy L, Quail MA, Samuel G, Skovsted IC, Kaltoft
MS, Barrell B, Reeves PR, Parkhill J, Spratt BG. 2006. Genetic analysis of the
capsular biosynthetic locus from all 90 pneumococcal serotypes. PLoS
Genet 2:e31. https://doi.org/10.1371/journal.pgen.0020031.
54. Satzke C, Dunne EM, Choummanivong M, Ortika BD, Neal EFG, Pell CL,
Nation ML, Fox KK, Nguyen CD, Gould KA, Hinds J, Chanthongthip A,
Xeuatvongsa A, Mulholland EK, Sychareun V, Russell FM. 2019. Pneumo-
coccal carriage in vaccine-eligible children and unvaccinated infants in
Lao PDR two years following the introduction of the 13-valent pneumo-
coccal conjugate vaccine. Vaccine 37:296–305. https://doi.org/10.1016/
j.vaccine.2018.10.077.
55. Porter BD, Ortika BD, Satzke C. 2014. Capsular serotyping of Streptococ-
cus pneumoniae by latex agglutination. J Vis Exp 91:e51747.
Oropharyngeal Samples for Adult Pneumococcal Carriage
July/August 2020 Volume 5 Issue 4 e00478-20 msphere.asm.org 15
 o
n
 August 7, 2020 by guest
http://m
sphere.asm
.org/
D
ow
nloaded from
 
